==== Front Cardiol Res Pract Cardiol Res Pract crp Cardiology Research and Practice 2090-8016 2090-0597 Hindawi 10.1155/2023/4528828 Research Article Outcomes of Combined Heart-Kidney Transplantation in Older Recipients https://orcid.org/0000-0002-5547-5156 Sherard Curry 1 Sama Vineeth 1 Kwon Jennie H. 2 https://orcid.org/0000-0002-9371-9350 Shorbaji Khaled 2 Huckaby Lauren V. 3 Welch Brett A. 2 Inampudi Chakradhari 4 Tedford Ryan J. 4 https://orcid.org/0000-0001-8112-8345 Kilic Arman kilica@musc.edu 2 1College of Medicine, Medical University of South Carolina, Charleston, SC, USA 2Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, USA 3Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA 4Department of Cardiology, Medical University of South Carolina, Charleston, SC, USA Academic Editor: Rongjun Zou 2023 24 6 2023 2023 452882817 9 2022 22 2 2023 5 6 2023 Copyright © 2023 Curry Sherard et al. 2023 https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objectives The upper limit of recipient age for combined heart-kidney transplantation (HKT) remains controversial. This study evaluated the outcomes of HKT in patients aged ≥65 years. Methods The United Network of Organ Sharing (UNOS) was used to identify patients undergoing HKT from 2005 to 2021. Patients were stratified by age at transplantation: <65 and ≥ 65 years. The primary outcome was one-year mortality. Secondary outcomes included 90-day and 5-year mortality, postoperative new-onset dialysis, postoperative stroke, acute rejection prior to discharge, and rejection within one-year of HKT. Survival was compared using Kaplan–Meier analysis, and risk adjustment for mortality was performed using Cox proportional hazards modeling. Results HKT in recipients aged ≥65 significantly increased from 5.6% of all recipients in 2005 to 23.7% in 2021 (p=0.002). Of 2,022 HKT patients in the study period, 372 (18.40%) were aged ≥65. Older recipients were more likely to be male and white, and fewer required dialysis prior to HKT. There were no differences between cohorts in unadjusted 90-day, 1-year, or 5-year survival in Kaplan–Meier analysis. These findings persisted after risk-adjustment, with an adjusted hazard for one-year mortality for age ≥65 of 0.91 (95% CI (0.63–1.29), p=0.572). As a continuous variable, increasing age was not associated with one-year mortality (HR 1.01 (95% CI (1.00–1.02), p=0.236) per year). Patients aged ≥65 more frequently required new-onset dialysis prior to discharge (11.56% vs. 7.82%, p=0.051). Stroke and rejection rates were comparable. Conclusion Combined HKT is increasing in older recipients, and advanced age ≥65 should not preclude HKT. ==== Body pmc1. Introduction Rates of combined heart-kidney transplantations (HKTs) have increased dramatically over the last decade and at a higher rate than isolated heart transplantation (HT) [1–3]. This increase has been driven in part by coexisting renal disease among heart transplant recipients, which has demonstrated a negative impact on survival following isolated HT [3–11]. In addition, recent studies have confirmed the survival benefit of HKT in patients with coexisting heart and renal failure. Importantly, the demand for donor hearts continues to prolong waitlist times for isolated HT and increase the number of patients using mechanical circulatory support, increasing the likelihood of second-organ failure [2, 12–15]. Kidney dysfunction affects the majority of patients awaiting HT, and severe dysfunction may not be reversible after isolated HT, necessitating consideration of HKT in these patients [2, 14]. Advanced age is associated with worse posttransplant survival in isolated heart and isolated kidney transplants, but the relationship between age and post-HKT survival has not been elucidated [5]. However, due to the lack of clear selection criteria, many centers consider advanced age 65 years and older as a contraindication for combined heart-kidney transplantation. There are limited data regarding outcomes among older patients who undergo HKT. The aim of this study was to evaluate trends and outcomes of HKT in patients aged 65 years or older compared to younger patients. 2. Materials and Methods 2.1. Study Design The United Network for Organ Sharing (UNOS) is a database that records all solid organ transplantations performed in the United States. The UNOS database was queried for all HKTs performed between January 1, 2005, and June 1, 2021. Only patients over 18 years of age were included in the analysis. This study was deemed exempt from review by the Medical University of South Carolina Institutional Review Board. Patients were grouped by age, either <65 years or ≥65 years at the time of transplantation. Baseline characteristics of recipients, donors, and recipient-donor matching were compared between the two age groups. The primary outcome was one-year mortality after HKT. Secondary outcomes included 90-day and 5-year mortality, postoperative new-onset dialysis, postoperative stroke, acute rejection prior to discharge, and rejection within one-year of HKT. 2.2. Statistical Analysis Categorical variables are summarized using counts and percentages. Pearson's chi-square tests were used to compare categorical variables, and Fisher's exact tests were used if the frequency of any variable was <5. All continuous variables were nonparametrically distributed and are presented as medians and interquartile ranges. Continuous variables were compared using Kruskal–Wallis tests. The Kaplan–Meier analysis was utilized to model 1-year survival, which was compared using log-rank tests and Wilcoxon-Breslow-Gehan tests. Multivariable Cox proportional hazards modeling was utilized to calculate the risk-adjusted hazard for recipient age on 1-year mortality after HKT. Covariates associated with 1-year mortality on univariable analysis with p < 0.20 were included in the final multivariable model as well as those retained after backward stepwise selection with p < 0.05. The threshold for statistical significance was two-sided p < 0.05. Analyses were performed using Stata, version 16.1 (StataCorp, TX, USA). 3. Results 3.1. Patient Cohort In the observed study period, 2,022 patients underwent HKT. The median age of the study population was 57 years, with 372 (18.4%) aged greater than 65 years. The age distribution of patients undergoing combined HKT is shown in Figure 1. There was a significant increase in the annual frequency of HKT in recipients aged 65 years and older from 5.6% of all HKT recipients in 2005 to 23.7% of all recipients in 2021 (p=0.002) (Figure 2). 3.2. Baseline Characteristics of the Study Population Demographic characteristics for HKT recipients stratified by age are summarized in Table 1. Notable characteristics associated with HKT recipients older than 65 included male sex (85.75% vs. 76.30%, p < 0.001), white race (61.83% vs. 48.97%, p < 0.001), lower creatinine (median Cr 2.2 vs. 2.7, p < 0.001), less dialysis prior to HKT (30.28% vs. 52.76%, p < 0.001), and fewer waitlist days (median 57.5 vs. 74.5, p = 0.039). Demographic characteristics for HKT donors to recipients aged ≥65 years included higher donor age (median 32 vs. 30, p < 0.001), Hispanic ethnicity (24.80% vs. 20.22%, p=0.014), and less HLA-matching at ≥3 loci (10.38% vs. 15.27%, p=0.016). 3.3. Kaplan–Meier Survival after Heart-Kidney Transplantation A Kaplan–Meier analysis of one-year survival after combined HKT stratified by recipient age is shown in Figure 3. The Kaplan–Meier analysis of 90-day and 5-year survival after combined HKT stratified by recipient age is shown in Figure 4. There were no differences between age groups in 90-day (92.0% in recipients aged <65 years vs. 91.7% in recipients aged ≥65 years, log-rank p=0.889), 1-year (87.5% vs. 88.2%, log-rank p=0.771, Breslow p=0.821), or 5-year (77.8% vs. 76.0%, log-rank p=0.748, Breslow p=0.992) survival in unadjusted Kaplan–Meier analysis. Secondary outcomes included dialysis prior to discharge (7.82% in younger patients vs. 11.56% in older patients, p=0.051), stroke prior to discharge (3.35% vs. 2.20%, p=0.375), rejection prior to discharge (8.30% vs. 9.68%, p=0.392), and rejection treated within one year posttransplant (8.66% vs. 7.92%, p=0.700). 3.4. One-Year Survival following Heart-Kidney Transplantation A multivariable Cox proportional hazards model for one-year mortality following combined HKT with age as a categorical variable is shown in Table 2. After risk adjustment, age ≥65 years was not associated with an increased risk for one-year mortality (HR 0.91, 95% CI, 0.63–1.29, p = 0.572). A multivariable Cox proportional hazards model for one-year mortality following combined HKT with age as a continuous variable is shown in Table 3. Increasing age was not associated with an increased risk for one-year mortality after HKT (HR 1.01 per year, 95% CI 1.00–1.02, p = 0.236). Increasing body mass index (BMI), increasing serum creatinine and bilirubin at time of HKT, mechanical ventilation prior to HKT, increasing heart ischemic time, and increasing donor age were found to independently predict one-year mortality after HKT. 3.5. Secondary Outcomes after Heart-Kidney Transplantation Secondary outcomes after combined HKT stratified by age are shown in Table 4. Patients aged ≥65 years had higher rates of new-onset dialysis after HKT prior to discharge, though this relationship was not significant (11.56% vs. 7.82%, p=0.051). There were no significant differences in rates of stroke prior to discharge, rejection prior to discharge, and rejection treated within one-year posttransplant between age groups. 4. Discussion Currently, there are few clearly defined recipient criteria for combined HKT and little data to suggest which recipients may benefit most from HKT compared to isolated HT [3, 4]. Previous studies have explored the impacts of comorbidities, age, and other recipient characteristics on survival post-HKT in an attempt to generate guidelines for dual organ allocation [5, 6, 13, 16, 17]. Advanced age in particular is a well-described independent risk factor for early and late mortality after isolated HT, although its effect on HKT is less defined. Early outcomes, including 1-year survival, freedom from rejection at 1-year, and absence of major adverse cardiac events in HKT recipients aged ≥65 years, have been shown to be similar to outcomes of isolated HT in this patient group [5]. In addition, analyses of longer term outcomes found that 5-year and 15-year survival after HKT among patients aged ≥60 years was comparable to younger patients [6, 13, 16]. Other factors studied include a threshold eGFR to recommend combined HKT versus isolated HT, with the conclusion that HKT should be recommended in patients with an eGFR <37 mL/minute as it improves posttransplant survival in this group as compared with isolated HT [1]. LVAD implantation has been shown to transiently improve eGFR in patients awaiting heart transplantation, but this effect is temporary and has no impact on survival [18]. Therefore, HKT offers a survival benefit to select patients with cardiorenal disease, which may extend to those of advanced age if selected appropriately. Peripheral vascular disease, recipient age >65 years, nonischemic heart failure, dialysis at the time of HKT, and mechanical circulatory support have previously been identified as factors associated with reduced survival following HKT [17]. The findings presented in this analysis demonstrate similar early posttransplant outcomes among recipients aged ≥65 years compared to their younger counterparts. These findings corroborate previous research that shows the lack of an adverse impact of advanced age on HKT outcomes. While one study by Reich et al. found that recipient age greater than 65 was associated with worse survival, the majority of previous studies found no difference in survival following HKT based on recipient age [5, 6, 13, 16, 17]. The similar survival rates between younger and older patients in these studies may be attributed to several factors. In a recent analysis by Punnoose et al., recipient selection appeared to mitigate any potential negative impact of advanced age on post-HKT survival [16]. Older patients had fewer severe comorbidities than younger patients but higher incidences of ischemic cardiomyopathy, and younger patients more frequently had risk factors such as smoking, dialysis dependence prior to transplant, mechanical circulatory support prior to transplant, and increased pulmonary artery pressure [16]. These differences illustrate the importance of comorbidities in predicting HKT outcomes rather than age alone. Another contributing factor to the similar overall outcomes of older patients could be related to the rates of graft rejection. Several studies have previously shown that older heart transplant recipients have lower rates of rejection and associated complications than younger recipients due to aging-related deterioration of the natural immune response [19, 20]. Aging has been associated with fewer alloreactive T cells and an increased susceptibility to immunosuppressive agents, producing a reduced rejection rate [20]. This study found that advanced recipient age was not associated with a similar incidence of rejection compared to age <65 years. Currently, there is a lack of guidelines regarding an upper limit of recipient age for HKT and minimal literature regarding this subject. The findings of the present study are consistent with the available literature on this matter, which recommend an individualized approach to HKT patient selection rather than a defined age cut-off [5]. Reich et al. recommended evaluation of factors, such as BMI, diabetic glycemic control, severe cerebral or peripheral vascular disease, frailty, social support, and severe cognitive-behavioral disabilities [5]. Additionally, Schaffer et al. described dialysis dependence in patients awaiting HT as an indication for HKT as opposed to isolated HT [15]. Given the findings of the present study that mechanical ventilation prior to HKT, increasing heart ischemic time, and increasing donor age independently predict 1-year mortality post HKT; these factors should also be considered in recipient evaluation and donor selection. Limitations of this study include selection bias as recipients aged 65 years or older were more likely to be of male sex, white race, and have lower creatinine, representing favorable risk characteristics at baseline. Following risk-adjustment, however, recipient age had no impact on increased risk for one-year mortality when modeled as a continuous or categorical variable. In addition, this analysis considered posttransplant complications only occurring before discharge and rejection occurring only within 1-year of transplant. Complications occurring after 1-year posttransplant are not captured by this analysis as these data are not widely available in the UNOS registry. Therefore, differences in longitudinal outcomes other than mortality between age groups are not analyzed here. Furthermore, registry data do not capture center-level practice differences between programs performing HKT. It is possible that only high volume, experienced centers are performing HKT in older patients, leading to improved outcomes and further contributing to selection bias. Lastly, the registry does not contain granular information on patient-specific factors such as perioperative care and postoperative transplant management that could impact survival. This analysis of the UNOS registry determined that advanced age ≥65 is not predictive of mortality after HKT. Data collected from this cohort indicate that recipient aged ≥65 years is associated with similar one- and five-year survival following HKT as compared with younger recipients. While comorbidities and other factors that are more common in older age may lead to negative outcomes, advanced age alone should not be used as an excluding variable for HKT candidacy. Data Availability The data that support the findings of this study are available on request to the United Network of Organ Sharing (UNOS) database. Conflicts of Interest The authors declare that they have no conflicts of interest. Dr. Kilic is a speaker and consultant for Abiomed, Abbott, 3ive, LivaNova. Figure 1 Age distribution of patients undergoing combined heart-kidney transplantation. Figure 2 Annual frequency of combined heart and kidney transplantation among recipients aged ≥65 years. Figure 3 Kaplan–Meier analysis of one-year survival after combined heart and kidney transplantation stratified by recipient age. Figure 4 Kaplan–Meier analysis of 90-day and 5-year survival after combined heart and kidney transplantation stratified by recipient age. Table 1 Demographic characteristics of patients undergoing heart-kidney transplantation stratified by age. Age <65 Age ≥65 p value N = 1,650 N = 372 81.60% 18.40% Recipient  Age (years), median (IQR) 54 (46, 60) 67 (66, 68) <0.001  Male sex, no. (%) 1,259 (76.30) 319 (85.75) <0.001  Race/ethnicity, no. (%)     <0.001   White 808 (48.97) 230 (61.83)     Black 589 (35.70) 91 (24.46)     Hispanic 146 (8.85) 32 (8.60)     Other 107 (6.48) 19 (5.11)    BMI (kg/m2), mean (SD) 26.5 (23.0, 30.3) 26.3 (23.9, 29.2) 0.916  Creatinine (mg/dL), median (IQR) 2.7 (1.9, 4.3) 2.2 (1.7, 3.1) <0.001  Dialysis prior to transplant, no. (%) 851 (52.76) 109 (30.28) <0.001  Total bilirubin (mg/dL), median (IQR) 0.7 (0.5, 1.1) 0.7 (0.5, 1.2) 0.293  Diabetes, no. (%) 716 (43.39) 173 (46.51) 0.275  Heart failure etiology, no. (%)     <0.001 Nonischemic cardiomyopathy 623 (37.76) 101 (27.15)     Ischemic cardiomyopathy 592 (35.88) 208 (55.91)     Hypertrophic/restrictive cardiomyopathy 105 (6.36) 36 (9.68)     Failed OHT 252 (15.27) 17 (4.57)     Congenital heart disease 31 (1.88) 1 (0.27)     Other/unknown 47 (2.85) 9 (2.42)    ICU at time of transplant, no. (%) 753 (46.54) 170 (46.70) 0.955  Mechanical ventilation, no. (%) 16 (0.97) 8 (2.15) 0.057  Bridging method     0.186   None 429 (26.00) 99 (26.61)     Inotropes 486 (29.45) 107 (28.76)     IABP 212 (12.85) 64 (17.20)     Durable VAD 414 (25.09) 82 (22.04)     Temporary VAD/ECMO 109 (6.61) 20 (5.38)    Karnofsky index, no. (%)     0.316   ≥80% 138 (8.94) 24 (6.72)     50–70% 346 (22.41) 88 (24.65)     ≤40% 1,060 (68.65) 245 (68.63)    Cardiac index (L/min/m2), median (IQR) 2.39 (1.94, 2.91) 2.36 (1.94, 2.90) 0.615  Mean PAP (mmHg), median (IQR) 30 (23, 37) 28 (23, 36) 0.121  Days on waitlist, median (IQR) 74.5 (22, 235) 57.5 (18, 185) 0.039  Heart ischemic time (hours), median (IQR) 32 (25, 38) 32 (25, 38) 0.703 Donor  Age (years), median (IQR) 30 (22, 39) 32 (24, 43) <0.001  Male sex, no. (%) 1,195 (72.42) 278 (74.73) 0.366  Race, no. (%)     0.014   White 1,026 (62.87) 224 (60.38)     Black 240 (14.71) 40 (10.78)     Hispanic 330 (20.22) 92 (24.80)     Other 36 (2.21) 15 (4.04)    Mechanism of death, no. (%)     0.506   Trauma 803 (48.67) 167 (44.89)     Cerebrovascular 310 (18.79) 73 (19.62)     Drug overdose 246 (14.91) 65 (17.47)     Other 291 (17.64) 67 (18.01)    BMI (kg/m2), mean (SD) 26.5 (23.3, 30.3) 26.2 (23.4, 30.3) 0.952  Diabetes, no. (%) 40 (2.44) 10 (2.72) 0.754  Recipient-donor matching   Sex-matched, no. (%) 1,242 (75.27) 283 (76.08) 0.745   Race-matched, no. (%) 679 (41.15) 116 (44.62) 0.220   HLA-matched, no. (%)b 248 (15.27) 39 (10.38) 0.016   ABO-identical, no. (%) 1,389 (84.18) 306 (82.26) 0.363   CMV-matched, no. (%)c 837 (50.73) 197 (52.96) 0.437 aDonor and recipient are considered HLA-matched if there are fewer than 4 mismatched loci. bAny combination other than CMV D-/R+. BMI, body mass index; CMV, cytomegalovirus; ECMO, extracorporeal membrane oxygenation; HLA, human leukocyte antigen; IABP, intraaortic balloon pump; PAP, pulmonary artery pressure; VAD, ventricular assist device. Table 2 Multivariable Cox proportional hazards model for one-year mortality following combined heart and kidney transplantation. Univariable analysis Final multivariable model Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value Age ≥65 0.95 (0.68–1.34) 0.771 0.91 (0.63–1.29) 0.572 Female recipient 1.11 (0.82–1.52) 0.476     Recipient race/ethnicity  White Reference Reference      Black 0.89 (0.66–1.19) 0.423      Hispanic 0.75 (0.44–1.26) 0.271      Other 1.16 (0.70–1.93) 0.562     Recipient BMI (per kg/m2) 1.04 (1.01–1.06) 0.006     Creatinine (per mg/dL) 1.04 (0.99–1.09) 0.110 1.05 (1.00–1.11) 0.035 Dialysis prior to transplant 1.32 (1.02–1.71) 0.038     Total bilirubin (per mg/dL) 1.03 (1.01–1.05) 0.002 1.03 (1.01–1.05) 0.002 Recipient diabetes 1.22 (0.94–1.57) 0.140     Cardiac diagnosis  NICM Reference Reference      Ischemic cardiomyopathy 1.17 (0.87–1.57) 0.303      HCM/RCM 1.20 (0.72–2.00) 0.490      Failed OHT 0.76 (0.48–1.22) 0.259      Congenital heart disease 1.20 (0.44–3.29) 0.717      Other/unknown 0.97 (0.42–2.22) 0.940     ICU at the time of transplantation 1.15 (0.89–1.50) 0.281     Mechanical ventilation at the time of transplantation 3.48 (1.72–7.04) 0.001 2.90 (1.33–6.31) 0.007 Bridging method  None Reference Reference Reference Reference  Inotropes 0.67 (0.46–0.97) 0.033 0.78 (0.53–1.15) 0.206  IABP 0.95 (0.61–1.47) 0.811 1.07 (0.68–1.69) 0.759  Durable VAD 1.10 (0.78–1.56) 0.578 1.26 (0.87–1.83) 0.220  Temporary VAD/ECMO 1.44 (0.87–2.39) 0.156 1.44 (0.82–2.52) 0.203 Karnofsky index, no. (%)  ≥80% Reference Reference      50–70% 1.58 (0.86–2.89) 0.142      ≤40% 1.55 (0.88–2.73) 0.129     Cardiac index (per L/min/m2) 1.00 (0.83–1.19) 0.965     Mean PAP (per mmHg) 1.03 (1.01–1.04) <0.001     Waitlist time (per day) 1.00 (1.00–1.00) 0.171     Ischemic time (per hour) 1.19 (1.06–1.33) 0.003 1.17 (1.04–1.31) 0.007 Donor age (per year) 1.01 (1.00–1.03) 0.011 1.02 (1.00–1.03) 0.007 Donor race/ethnicity  White Reference Reference      Black 1.11 (0.77–1.61) 0.574      Hispanic 0.86 (0.61–1.22) 0.399      Other 1.77 (0.93–3.35) 0.082     Mechanism of death  Trauma Reference Reference      Cerebrovascular 1.35 (0.96–1.88) 0.082      Drug overdose 1.09 (0.73–1.63) 0.657      Other 1.27 (0.89–1.80) 0.187     Donor BMI (per kg/m2) 1.01 (0.99–1.03) 0.277     Donor diabetes 1.07 (0.48–2.42) 0.861     Sex-matched 1.04 (0.77–1.40) 0.781     Race-matched 1.08 (0.83–1.40) 0.583     HLA-matched 1.28 (0.86, 1.95) 0.210     ABO-identical 1.06 (0.75, 1.49) 0.755     BMI, body mass index; CMV, cytomegalovirus; ECMO, extracorporeal membrane oxygenation; HLA, human leukocyte antigen; IABP, intraaortic balloon pump; PAP, pulmonary artery pressure; VAD, ventricular assist device. Age as categorical variable. Table 3 Multivariable Cox proportional hazards model for one-year mortality following combined heart and kidney transplantation. Univariable analysis Final multivariable model Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value Age (per year) 1.01 (1.00–1.02) 0.262 1.01 (1.00–1.02) 0.236 Creatinine (per mg/dL) 1.04 (0.99–1.09) 0.110 1.06 (1.01–1.12) 0.014 Total bilirubin (per mg/dL) 1.03 (1.01–1.05) 0.002 1.03 (1.01–1.05) 0.002 Mechanical ventilation at time of transplantation 3.48 (1.72–7.04) 0.001 2.85 (1.31–6.22) 0.008 Bridging method  None Reference Reference Reference Reference  Inotropes 0.67 (0.46–0.97) 0.033 0.78 (0.53–1.15) 0.210  IABP 0.95 (0.61–1.47) 0.811 1.06 (0.67–1.66) 0.807  Durable VAD 1.10 (0.78–1.56) 0.578 1.26 (0.87–1.83) 0.872  Temporary VAD/ECMO 1.44 (0.87–2.39) 0.156 1.49 (0.85–2.62) 0.852 Ischemic time (per hour) 1.19 (1.06–1.33) 0.003 1.17 (1.04–1.32) 0.007 Donor age (per year) 1.01 (1.00–1.03) 0.011 1.02 (1.00–1.03) 0.012 ECMO, extracorporeal membrane oxygenation; IABP, intraaortic balloon pump; VAD, ventricular assist device. Age as continuous variable. Only age and covariates associated with one-year mortality on univariable analysis are listed here. Table 4 Secondary outcomes after combined heart-kidney transplantation stratified by age group. Age <65 Age ≥65 p value N = 1,650 N = 372 81.60% 18.40% Dialysis prior to discharge 129 (7.82) 43 (11.56) 0.051 Stroke prior to discharge 54 (3.35) 8 (2.20) 0.375 Rejection prior to discharge 137 (8.30) 36 (9.68) 0.392 Rejection treated within one year posttransplant 100 (8.66) 21 (7.92) 0.700 ==== Refs 1 Karamlou T. Welke K. F. McMullan D. M. Combined heart-kidney transplant improves post-transplant survival compared with isolated heart transplant in recipients with reduced glomerular filtration rate: analysis of 593 combined heart-kidney transplants from the United Network Organ Sharing Database The Journal of Thoracic and Cardiovascular Surgery 2014 147 1 456 461.e1 10.1016/j.jtcvs.2013.09.017 2-s2.0-84890549937 24183335 2 Wayda B. Cheng X. S. Goldhaber‐Fiebert J. D. Khush K. K. Optimal patient selection for simultaneous heart‐kidney transplant: a modified cost‐effectiveness analysis American Journal of Transplantation 2022 22 4 1158 1168 10.1111/ajt.16888 34741786 3 Rafat C. Hertig A. Rondeau E. Renal impairment an impediment to heart transplantation? Iran J Kidney Dis 2015 9 2 77 83 25851285 4 Johnson M. R. Nadim M. K. Simultaneous heart‐kidney transplant: working together to define when one organ is not enough American Journal of Transplantation 2021 21 7 2323 2324 10.1111/ajt.16564 33721402 5 Reich H. Dimbil S. Levine R. Dual-organ transplantation in older recipients: outcomes after heart–kidney transplant versus isolated heart transplant in patients aged ≥65 years Interactive Cardiovascular and Thoracic Surgery 2018 28 1 45 51 10.1093/icvts/ivy202 2-s2.0-85058918084 6 Awad M. A. Czer L. S. Emerson D. Combined heart and kidney transplantation: clinical experience in 100 consecutive patients Journal of the American Heart Association 2019 8 4 e010570 10.1161/jaha.118.010570 2-s2.0-85061287229 7 McCartney S. L. Patel C. Del Rio J. M. Long-term outcomes and management of the heart transplant recipient Best Practice & Research Clinical Anaesthesiology 2017 31 2 237 248 10.1016/j.bpa.2017.06.003 2-s2.0-85023771794 29110796 8 Taiwo A. A. Khush K. K. Stedman M. R. Zheng Y. Tan J. C. Longitudinal changes in kidney function following heart transplantation: stanford experience Clinical Transplantation 2018 32 11 e13414 10.1111/ctr.13414 2-s2.0-85055483516 9 Khush K. K. Cherikh W. S. Chambers D. C. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult heart transplantation report-2018; focus theme: multiorgan transplantation The Journal of Heart and Lung Transplantation 2018 37 10 1155 1168 10.1016/j.healun.2018.07.022 2-s2.0-85054173722 30293612 10 Libório A. Uchoa R. Neto J. Valdivia J. Daher E. D. F. Mejia J. Assessing glomerular filtration rate in patients with severe heart failure: comparison between creatinine-based formulas Sao Paulo Medical Journal 2012 130 5 289 293 10.1590/s1516-31802012000500004 2-s2.0-84870613311 23174867 11 Labban B. Crew R. J. Cohen D. J. Combined heart-kidney transplantation: a review of recipient selection and patient outcomes Advances in Chronic Kidney Disease 2009 16 4 288 296 10.1053/j.ackd.2009.05.003 2-s2.0-67649336425 19576559 12 Parekh J. R. Lam J. Chau H. Berumen J. Schnickel G. T. Mekeel K. Impact of diabetes and chronic dialysis on post‐transplant survival in combined heart‐kidney transplant recipients Clinical Transplantation 2021 35 7 e14338 10.1111/ctr.14338 13 Czer L. S. Awad M. De Robertis M. A. Combined heart and kidney transplant: a 23 year experience The Journal of Heart and Lung Transplantation 2016 35 4 S138 S139 10.1016/j.healun.2016.01.381 14 Heywood J. T. Fonarow G. C. Costanzo M. R. Mathur V. S. Wigneswaran J. R. Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database Journal of Cardiac Failure 2007 13 6 422 430 10.1016/j.cardfail.2007.03.011 2-s2.0-34547542423 17675055 15 Schaffer J. M. Chiu P. Singh S. K. Oyer P. E. Reitz B. A. Mallidi H. R. Heart and combined heart-kidney transplantation in patients with concomitant renal insufficiency and end-stage heart failure American Journal of Transplantation 2014 14 2 384 396 10.1111/ajt.12522 2-s2.0-84895064360 24279876 16 Punnoose L. R. Rao S. Ghanta M. M. Karhadkar S. S. Alvarez R. Outcomes of older patients in the recent era of heart kidney transplantation Transplantation Proceedings 2021 53 1 341 347 10.1016/j.transproceed.2020.04.1821 32694056 17 Russo M. J. Rana A. Chen J. M. Pretransplantation patient characteristics and survival following combined heart and kidney transplantation: an analysis of the United Network for Organ Sharing Database Archives of surgery 2009 144 3 241 246 10.1001/archsurg.2008.559 2-s2.0-63149176570 19289663 18 Zittermann A. Schramm R. Becker T. Renal function in patients with or without a left ventricular assist device implant during listing for a heart transplant Annals of Transplantation 2020 25 e925653 10.12659/AOT.925653 19 Jaiswal A. Gadela N. V. Baran D. Clinical outcomes of older adults listed for heart transplantation in the United States Journal of the American Geriatrics Society 2021 69 9 2507 2517 10.1111/jgs.17271 34105139 20 Wever-Pinzon O. Edwards L. B. Taylor D. O. Association of recipient age and causes of heart transplant mortality: implications for personalization of post-transplant management—an analysis of the International Society for Heart and Lung Transplantation Registry The Journal of Heart and Lung Transplantation 2017 36 4 407 417 10.1016/j.healun.2016.08.008 2-s2.0-84995575836 27686602